Impact of inclusion of industry trial results registries as an information source for systematic reviews

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Potthast, Regine ^a   Vervölgyi, Volker ^a   McGauran, Natalie ^a   Kerekes, Michaela F ^a   Wieseler, Beate ^a   Kaiser, Thomas ^a  

^a INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; EZETIMIBE; MILNACIPRAN; NEUROLEPTIC AGENT; OLANZAPINE; REBOXETINE; SERTRALINE; SIBUTRAMINE; SIMVASTATIN; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE;

ARTICLE; BIPOLAR DISORDER; CLINICAL STUDY; DATA BASE; DATA EXTRACTION; DELUSIONAL DISORDER; DRUG INDUSTRY; HUMAN; HYPERCHOLESTEROLEMIA; INFORMATION SYSTEM; MAJOR DEPRESSION; NON PROFIT ORGANIZATION; OBESITY; POLICY; PSYCHOSIS; PUBLICATION; REGISTER; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; STUDY DESIGN; SYSTEMATIC REVIEW (TOPIC); CLINICAL TRIAL (TOPIC); LITERATURE; MEDLINE; RESEARCH; STATISTICS AND NUMERICAL DATA;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; PUBMED; REGISTRIES; RESEARCH REPORT; REVIEW LITERATURE AS TOPIC;

EID: 84899755517     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092067     Document Type: Article

References (78)

1. Hopewell S, McDonald S, Clarke M, Egger M (2007) Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev: MR000010.
2. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252-260.
3. Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, et al. (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341: c4737.
4. Simes RJ (1986) Publication bias: the case for an international registry of clinical trials. J Clin Oncol 4: 1529-1541. (Pubitemid 17183579)
5. Dickersin K, Rennie D (2003) Registering clinical trials. JAMA 290: 516-523. (Pubitemid 37448502)
6. Krleza-Jeric K, Chan AW, Dickersin K, Sim I, Grimshaw J, et al. (2005) Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ 330: 956-958. (Pubitemid 40592318)
7. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, et al. (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 351: 1250-1251. (Pubitemid 39296312)
8. Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, et al. (2007) Clinical trial registration. BMJ 334: 1177-1178. (Pubitemid 46954571)
9. Sim I, Chan AW, Gulmezoglu AM, Evans T, Pang T (2006) Clinical trial registration: transparency is the watchword. Lancet 367: 1631-1633. (Pubitemid 43728234)
10. United States Congress (2007) Food and Drug Administration Amendments Act (FDAAA) of 2007: public law no. 110-85. Available: http://www.gpo.gov/fdsys/ pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf. Accessed 4 September 2013.
11. Groves T (2008) Mandatory disclosure of trial results for drugs and devices. BMJ 336: 170. (Pubitemid 351212652)
12. European Agency for the Evaluation of Medicinal Products (2004) EMEA launches EudraCT database. Available: http://www.ema.europa.eu/docs/en- GB/document-library/Press-release/2009/11/WC500015292.pdf. Accessed 4 September 2013.
13. European Medicines Agency (2013) EudraCT: European Union Drug Regulating Authorities Clinical Trials [Website]. Available: https://eudract. ema.europa.eu/. Accessed 6 Aug 2013.
14. McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, et al. (2010) Reporting bias in medical research: a narrative review. Trials 11: 37.
15. Pharmaceutical Research and Manufacturers of America (2002) Principles on conduct of clinical trials and communication of clinical trial results.
16. International Federation of Pharmaceutical Manufacturers and Associations (2005) Joint position on the disclosure of clinical trial information via clinical trial registries and databases.
17. Pharmaceutical Research and Manufacturers of America (2011) Principles on the conduct of clinical trials; communication of clinical trial results. Available: http://phrma.org/sites/default/files/pdf/042009-clinical-trial- principles- final-0.pdf. Accessed 5 September 2013.
18. International Federation of Pharmaceutical Manufacturers and Associations (2009) Joint position on the disclosure of clinical trial information via clinical trial registries and databases. Available: http://clinicaltrials.ifpma. org/clinicaltrials/fileadmin/files/pdfs/EN/November-10-2009-Updated-Joint- Position-on-the-Disclosure-of-Clinical-Trial-Information-via-Clinical-Trial- Registries- and-Databases.pdf. Accessed 4 September 2013.
19. Office of the Attorney General (2004) Settlement sets new standard for release of drug information. Available: http://www.ag.ny.gov/press-release/ settlement-sets-new-standard-release-drug-information. Accessed 19 September 2013.
20. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471. (Pubitemid 46919772)
21. European Medicines Agency (2010) European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim: anti-diabetes medication to be taken off the market. Available: http://www.ema.europa.eu/ema/index. jsp?curl=pages/news-and-events/news/2010/09/news-detail-001119. jsp&mid=WC0b01ac058004d5c1. Accessed 9 December 2013.
22. Food and Drug Administration (2010) FDA significantly restricts access to the diabetes drug Avandia. Available: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm226956.htm. Accessed 9 December 2013.
23. Food and Drug Administration, editor (2011) Approved drug products with therapeutic equivalence evaluations: 31st edition. Rockville: FDA.
24. Wood AJJ (2009) Progress and deficiencies in the registration of clinical trials. N Engl J Med 360: 824-830.
25. Cipriani A, Rendell JM, Geddes J (2009) Olanzapine in long-term treatment for bipolar disorder. Cochrane Database Syst Rev: CD004367.
26. De Lemos HP Jr, Atallah AN, Alves De Lemos AL (2008) Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis. Sao Paulo Med J 126: 342-346.
27. Schwarz C, Volz A, Li C, Leucht S (2008) Valproate for schizophrenia. Cochrane Database Syst Rev: CD004028.
28. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, et al. (2009) Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev: CD006529.
29. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, et al. (2009) Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev: CD006117.
30. Ara R, Tumur I, Pandor A, Duenas A, Williams R, et al. (2008) Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Assess 12: iii, xi-xiii, 1-212.
31. Wieseler B, Kerekes MF, Vervoelgyi V, McGauran N, Kaiser T (2012) Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ 344: d8141.
32. Wieseler B, Wolfram N, McGauran N, Kerekes MF, Vervolgyi V, et al. (2013) Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Med 10: e1001526.
33. Moja LP, Moschetti I, Nurbhai M, Compagnoni A, Liberati A, et al. (2009) Compliance of clinical trial registries with the World Health Organization minimum data set: a survey. Trials 10: 56.
34. Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, et al. (2013) Non-publication of large randomized clinical trials: cross sectional analysis. BMJ 347: f6104.
35. Turner EH, Moaleji NJ, Arnold BL (2008) Closing a loophole in the FDA Amendments Act. Science 322: 44-46.
36. Schroll J (2013) Deaths in trials should always be reported. BMJ 347:f4219
37. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, et al. (2008) Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One 3: e3081. Available: http://www.plosone.org/article/ info%3Adoi%2F10.1371%2Fjournal.pone.0003081. Accessed 4 September 2013.
38. Chan AW, Altman DG (2005) Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ 330: 753.
39. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine: selective reporting from studies sponsored by pharmaceutical industry; review of studies in new drug applications. BMJ 326: 1171-1173. (Pubitemid 36649049)
40. Vedula SS, Bero L, Scherer RW, Dickersin K (2009) Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med 361: 1963-1971.
41. Rasmussen N, Lee K, Bero L (2009) Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials 10: 116.
42. Jorgensen AW, Hilden J, Gotzsche PC (2006) Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 333: 782.
43. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326: 1167-1170. (Pubitemid 36649048)
44. Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289: 454-465. (Pubitemid 36119966)
45. Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM (2009) Trial publication after registration in clinicaltrials.gov: a cross-sectional analysis. PLoS Med 6: e1000144. Available: http://www.plosmedicine.org/article/ info%3Adoi%2F10.1371%2Fjournal.pmed.1000144. Accessed 4 September 2013.
46. Veitch E (2012) Silent takedown of the pharma trials database and more. In: PLOS Blogs. Available: http://blogs.plos.org/speakingofmedicine/2012/03/23/ silent-takedown-of-the-pharma-trials-database%E2%80%A6and-more/. Accessed 8 August 2013.
47. European Medicines Agency (2010) European Medicines Agency widens public access to documents: policy on access to documents also sets out new approach for proactive disclosure of documents. Available: www.ema.europa.eu/ema/index. jsp?curl=pages/news-and-events/news/2010/11/news-detail-001158. jsp&mid=WC0b01ac058004d5c1&murl=menus/news-and-events/news- and-events.jsp. Accessed 9 December 2013.
48. European Medicines Agency (2013) Draft policy 70: publication and access to clinical-trial data. Available: http://www.emea.europa.eu/ema/index.jsp?curl= pages/includes/document/document-detail.jsp?webContentId=WC500144730&mid= WC0b01ac058009a3dc. Accessed 1 July 2013.
49. Jack A (2013) Pharma group sues European regulator over data. Financial Times. Available: http://www.ft.com/cms/s/0/9956b5ca-899f-11e2-92a0- 00144feabdc0.html#axzz2dug4fbrM. Accessed 4 September 2013.
50. Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG (2007) Epidemiology and reporting characteristics of systematic reviews. PLoS Med 4: e78. Available: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal. pmed.0040078. Accessed 4 September 2013.
51. Lefebvre C, Manheimer E, Glanville J (2008) Searching for studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. New York: Wiley. pp. 95-150.
52. van Enst WA, Scholten RJ, Hooft L (2012) Identification of additional trials in prospective trial registers for Cochrane systematic reviews. PLoS One 7: e42812. Available: http://www.plosone.org/article/info%3Adoi%2F10. 1371%2Fjournal.pone.0042812. Accessed 4 September 2013.
53. Schroll JB, Bero L, Gotzsche PC (2013) Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ 346: f2231.
54. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6: e1000100. Available: http://www.plosmedicine.org/article/ info%3Adoi%2F10.1371%2Fjournal.pmed.1000100. Accessed 9 December 2013
55. Abbott Laboratories A randomized, double-blind study of the safety and efficacy of Depakote ER plus an atypical antipsychotic vs. an atypical antipsychotic alone in the treatment of schizophrenia: clinical study report M02-547. In: ClinicalStudyResults.org. Available: http://www. clinicalstudyresults.org/documents/company-study-782-0.pdf. Accessed 4 October 2009 (no longer available).
56. Now available: http://www.abbott.com/static/cms-workspace/content/ document/Citizenship/clinical-study-results/divalproex-sodium- M02-547-study.pdf. Accessed 25 November 2013.
57. Abbott Laboratories (2006) Blood pressure and weight trajectory on a dual antihypertensive combination plus sibutramine versus placebo in obese hypertensives: clinical study report KD 200010. In: ClinicalStudyResults.org. Available: http://www.clinicalstudyresults.org/documents/company-study- 1275-0.pdf. Accessed 24 February 2010 (no longer available).
58. Now available: http://www.abbott.com/static/cms-workspace/content/ document/Citizenship/clinical-study-results/sibutramine-kd200010-study.pdf Accessed 25 November 2013.
59. Abbott Laboratories (2006) Randomized trial of obese non-diabetic Malaysians using sibutramine: a randomized double-blind placebo-controlled study of sibutramine in the management of obese subjects in Malaysia; clinical trial report MLAY02001. In: ClinicalStudyResults.org. Available: http://www. clinicalstudyresults.org/documents/company-study-4130-0.pdf. Accessed 24 February 2010 (no longer available).
60. Now available: http://www.abbott.com/static/cms-workspace/content/ document/Citizenship/clinical-study-results/sibutramine-mlay-02-001-study.pdf. Accessed 25 November 2013
61. Abbott Laboratories A multicenter, double-blind, randomized, placebo-controlled, parallel group study to examine the longer-term efficacy and safety of Meridia (sibutramine hydrochloride) in obese subjects; clinical study report SB118. In: ClinicalStudyResults.org. Available: http://www. clinicalstudyresults. org/documents/company-study-1146-0.pdf. Accessed 24 February 2010 (no longer available).
62. Now available: http://www.abbott.com/static/cms- workspace/content/ document/Citizenship/clinical-study-results/sibutramine- sb118-study.pdf. Accessed 25 November 2013.
63. Berkowitz RI, Fujioka K, Daniels SR, Hoppin AG, Owen S, et al. (2006) Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 145: 81-90. (Pubitemid 46780581)
64. Eli Lilly (2004) Olanzapine added to mood stabilizer for relapse prevention in patients with bipolar disorder: CT registry ID#1035b. In: ClinicalStudyResults.org. Available: http://www.clinicalstudyresults.org/ documents/company-study-173-0.pdf. Accessed 13 April 2009 (no longer available).
65. Now available: http://www.lillytrials.com/results/Zyprexa.pdf. Accessed 25 November 2013.
66. Eli Lilly (2004) Olanzapine versus placebo in the prevention of relapse in bipolar disorder: clinical study summary; study F1D-MC-HGHL. In: ClinicalStudyResults.org. Available: http://www.clinicalstudyresults.org/ documents/company-study-1164-0.pdf Accessed 13 April 2009 (no longer available).
67. Now available: http://www.lillytrials.com/results/Zyprexa.pdf. Accessed 25 November 2013.
68. Eli Lilly (2004) Olanzapine versus divalproex in the treatment of acute mania: clinical study summary; study F1D-US-HGHQ. In: ClinicalStudyResults.org. Available: http://www.clinicalstudyresults.org/documents/company-study- 176-0.pdf. Accessed 13 April 2009 (no longer available).
69. Now available: http://www.lillytrials.com/results/Zyprexa.pdf. Accessed 25 November 2013.
70. Eli Lilly (2004) Olanzapine versus lithium in relapse prevention in bipolar disorder: clinical study summary; study F1D-MC-HGHT. In: ClinicalStudyResults.org. Available: http://www.clinicalstudyresults.org/ documents/company-study-603-0.pdf. Accessed 13 April 2009 (no longer available).
71. Now available: http://www.lillytrials.com/results/Zyprexa.pdf. Accessed 25 November 2013.
72. 17 response rate: protocol 0600B1-816. In: ClinicalStudyResults.org. Available: http://www.clinicalstudyresults.org/documents/company-study- 9750-1.pdf. Accessed 20 February 2010 (no longer available).
73. Pfizer (2008) Sertraline/[S, S]-reboxetine combination versus sertraline and [S, S]-reboxetine monotherapy in major depressive disorder (MDD) in a double-blind, placebo-controlled, eight week study: protocol no. A0501075. In: ClinicalStudyResults.org. Available: www.clinicalstudyresults.org. Accessed 20 February 2010 (no longer available).
74. Pfizer (2008) A multicenter randomized, double-blind, parallel-group study of sertraline versus venlafaxine XR in the acute treatment of outpatients with major depressive disorder. In: Clinical Study Results Database. Available: www.clinicalstudyresults.org. Accessed 20 February 2010 (no longer available).
75. Glaxo Smith Kline (2005) A multicenter, double-blind, placebo-controlled comparison of the effects on sexual functioning of wellbutrin (bupropion HCI) sustained release and sertraline in outpatients with moderate to severe recurrent major depression (WELL AK1A4001). In: Clinical Study Results Database. Available: www.clinicalstudyresults.org Accessed 20 February 2010 (no longer available).
76. Glaxo Smith Kline (2005) A multicenter, double-blind, placebo-controlled comparison of the effects on sexual functioning of wellbutrin (bupropion HCl) sustained release and sertraline in outpatients with moderate to severe recurrent major depression (WELL AK1A4002). In: Clinical Study Results Database. Available: www.clinicalstudyresults.org Accessed 20 February 2010 (no longer available).
77. Glaxo Smith Kline (2005) The safety and efficacy of wellbutrin sustained release and sertraline in depressed outpatients. In: Clinical Study Results Database. Available: www.clinicalstudyresults.org Accessed 20 February 2010 (no longer available).
78. Merck (2005) A multicenter, double-blind, randomized study to evaluate the lipid-altering efficacy, safety, and tolerability of ezetimibe coadministered with simvastatin versus simvastatin monotherapy in African-American subjects with primary hypercholesterolemia (protocol no. P03377). In: ClinicalStudyResults. org. Available: www.clinicalstudyresults.org. Accessed 10 July 2011 (no longer available).